Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy

Journal article

Peer reviewed

Semir Vranic and Zoran Gatalica

Biomolecules & biomedicine, Vol.24(4), pp.673-675

08/01/2024

PMID: 38656302

Abstract

Life Sciences & Biomedicine

Medicine, Research & Experimental

Research & Experimental Medicine

Science & Technology

url

https://doi.org/10.17305/bb.2024.10641View

Published (Version of record) Open

1 Record Views

Title: Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy
Creators: Semir Vranic - Qatar University
Zoran Gatalica - College Station Medical Center
Publication Details: Biomolecules & biomedicine, Vol.24(4), pp.673-675
Publisher: Assoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo
Number of pages: 3
Identifiers: 991006263873802656
Academic Unit: Pathology
Language: English
Resource Type: Journal article